ZIOPHARM ONCOLOGY INC Form 8-K October 28, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 28, 2011

ZIOPHARM Oncology, Inc. (Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-33038 (Commission File Number) 84-1475672 (IRS Employer Identification No.)

1180 Avenue of the Americas 19th Floor New York, NY

10036 (Zip Code)


New York, NY
(Address of Principal Executive Offices)

(646) 214-0700 (Registrant's telephone number, including area code)

Not applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR



Item 8.01 Other Events

On October 28, 2011, the Company issued a press release announcing the presentation of preclinical data with palifosfamide (ZymafosTM or ZIO-201) in a pediatric sarcoma model. The data was detailed in an oral session of the 2011 meeting of the combined Connective Tissue Oncology Society (CTOS) Musculoskeletal Tumor Society (MSTS), being held October 26 - 29, 2011 in Chicago, IL.

A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report of Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release of the Company dated October 28, 2011

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

By: /s/ Richard Bagley

Name: Richard Bagley

Title: President, Chief Operating Officer

and Chief Financial Officer

3

Date: October 28, 2011

INDEX OF EXHIBITS

Exhibit No. Description

99.1 Press Release of the Company dated October 28, 2011

4